Bioxyne holds a health and wellness product portfolio which includes health supplements, skincare, probiotics, cannabis-derived raw materials, starting materials, API’s, THC- and CBD-based therapies, telemedicine technology and involves controlled substances licenses in Australia.
The company holds licenses to import, export, wholesale and manufacture schedule 3, 4 and 8 controlled substances, including medical cannabis and ketamine in Australia.
DRUG PROGRAMS TARGET: Depression, PTSD, chronic pain, sleep, gut health, cognitive function, hormonal balance, energy, immune support and certain neurological conditions.
SUBSTANCE FOCUS: Psilocybin, MDMA, THC and CBD
OWNERSHIP:
100% – Breathe Life Sciences is a licensed manufacturer, sponsor, importer and exporter of controlled substances in Australia. The group is headquartered in Sydney and has offices in London, Manchester, Prague, Brisbane as well as Nagoya and has been involved in medical cannabis since 2020, partnering with GACP cultivators and GMP manufacturers globally in Canada, South America, South Africa, Europe, the UK and Thailand. They source quality materials at competitive prices for GMP-manufacturing and supply in the Australian market where its subsidiary, BLS Wholesalers is a licensed importer, manufacturer, and wholesaler. BLS offers unique cannabis profiles and strains, serving manufacturers, pharmacies, and patients. BLS serves 600+ business clients.
FACILITIES:
Brisbane manufacturing facility
NEWS & PARTNERSHIPS:
2016
The company launched Progastrim, a probiotic product for gut and immune health and protract, for atopic dermatitis into the Australian market, with both products containing the company’s patented probiotic PCC which is a strain of Lactobacillus fermentum.
2017
The company received a direct sales license in Malaysia where it launched BK18, a dairy-based nutritional product formulated and manufactured in New Zealand. The company also received a purchase order for 16,000 cans of BK18 for other Southeast Asian countries outside of Malaysia. The company established a showroom and an office in Kuala Lumpur which will serve as its regional office to support its expansion in the region and the company is also developing direct sales business in other Asian countries, including Vietnam, Indonesia and Taiwan.
2018
The company paid 121,000 AUD and acquired a 95% ownership in PT Gamat Utama an Indonesian direct sales company distributing a range of health products and supplements, with 2,500 distribution members. PTG will receive an additional 44,000 AUD if sales exceed 450,000 AUD in 2019 and Bioxyne is required to capitalize PTG up to an equivalent amount of 900,000 AUD to comply with Indonesian foreign investment regulations.
The company made a deal with AVSA International for the exclusive distribution of Bioxyne’s products to Thailand, Philippines, Myanmar, Cambodia and Mauritius with a first order placed with the value of 266,000 AUD. The deal includes a call option giving the company the right to acquire a 70 per cent interest in the business in each country before July 2021. The product range to be sold is the Bioxyne Mustang nutritional shake for men, Bioxyne Progastrim adult probiotics for gut and immune health, Bioxyne proTract infant probiotics for treating atopic dermatitis, the B18 dairy-based nutritional health drink, the women’s weight-loss and beauty product Allura and its bee-venom, collagen-peptide, stem-cell-extract and harakeke-flax-gel beauty serum BEssense. ASVA will manage and distribute the products in these 5 countries and will be supported by Byoxine’s direct sales system and platform and will be excluded from selling competing products.
2022
The company solds its 49% share of its Direct Selling group of companies to a Singapore-based private equity group, Paramount Star Investments for 1 million AUD.
2023
The company acquired Breathe Life Sciences which manufactures and sells plant and mushroom-based wellness products, health supplements and nootropics including CBD, cannabis extracts, vitamins, manka honey, skin care products, mushroom complexes and medicinal cannabis to consumers and businesses. BLS operates in Australia, the UK, Japan and Europe and has 4 accredited manufacturing facilities in Japan, Australia, the UK and the Czech Republic as well as a team of 30 people.
BLS launched BLS Clinics, online healthcare made possible in cooperation with Powered by InstantScripts which has a network of 120+ doctors and the clinics fulfill scripts for plant-based therapies through its partner pharmacies. The clinic was created to provide plant-based therapies for patients with chronic health conditions.
Dr. Watson-branded mushroom products launched on Amazon in the US and a broader range of products launched in Japan.
The company executed a JV deal with CanXChange, Europe’s biggest cannabis B2B online marketplace, for the creation of an AI-powered B2B therapeutic goods platform in Australia. The platform will facilitate wholesale trading between licensed buyers, sellers, cultivators, pharmacies and accredited manufacturers in the country, as well as internationally.
2024
The company launched its invite-only B2B trading platform with CanxChange in Australia with over 10 million AUD in leads uploaded in the first week. The only cost of using the platform is a small percentage fee for the service, shared between purchaser and seller.
The company manufactured and delivered Australia’s first pharmaceutical-grade cannabis edibles through its gummies with CBD and/or THC. They also signed a 2-year manufacturing and supply agreement with one of Australia’s largest cannabis companies and scaled up their gummy manufacturing capabilities to 6 million per month from 2 million.
The company signed a supply and collaboration agreement with CY Biopharma to develop groundbreaking mental health and pain treatmetments for Australia and New Zealand. The company will manufacture and supply the Australian, New Zealand, US, and European clinical trials market with novel psilocybin products, to develop proprietary formulations and drug delivery methods and to supply to Australian patients via the authorized prescriber scheme. Cy Biopharma will exclusively supply BLS with Psilocybe cubensis mushrooms for Australia and New Zealand.
The company was awarded a GMP-manufacturing license for medical cannabis as well as Australia’s first GMP license to manufacture psilocybin and MDMA API’s as well as final dose form capsules for supply to authorized prescribers and clinical trials. What followed was an upgraded and amended wholesale licence for MDMA and Psilocybin finished products by the TGA.
The company released 4 white label batch manufacturing runs before the 31st of March, with secured orders from the quarter before being worth 1.4 million AUD.
2026
The company’s subsidiary Breathe Life Sciences signed a manufacturing agreement with Aurora Cannabis via its Australian entity MedReleaf Australia where BLS will manufacture GMP-certified cannabis oils for Aurora in Australia. The agreement also covers vape products for supply in Australia, the UK, and Germany.
Breathe Life Sciences secured its first medicinal cannabis flower supply agreement in Costa Rica through a deal with Remidose LATAM.
The company’s subsidiary Breathe Life Sciences secured a 2-year $50 million exclusive German supply agreement with German pharma company ADREXpharma. Exclusive rights for the Dr Watson brand in Germany was given for a $25M minimum commitment in the first 12 months.
BRANDS:
Dr Watson was established in 2019 when it launched its range of CBD lifestyle and consumer health products in the UK followed by Japan with an expansion of its medical cannabis range supplying pharmacies and clinics in Australia. Products offered come as gummies, vapes, oral mucosal oils, flower as well as suppositories and is approved by Amazon for CBD
Probiotic PCC
The company’s clinically tested probiotic is Lactobacillus fermentum VRI-003 PCC.
Probiotic sales are led by ProBio PCC, a probiotic product containing PCC and is sold exclusively and globally by Nu-Skin Enterprises.
Bioxyne sells its own branded PCC-containing products in Australia called Progastrim for gut and immune health and proTract for atopic dermatitis. In the US
Apothecary CBD holds skincare solutions for eczema, dermatitis, dry skin and acne. The range is sold through Amazon UK.
MYMANA is the company’s formulation of colostrum, dairy milk formula and honey which is sourced from New Zealand as scientists and is boosted with vitamins and minerals for sustained energy.